# Impact of Monacolin K‐Containing Supplements on Lipid Profile: A Meta‐Analysis of Randomised Controlled Trials

## TL;DR

This study finds that supplements containing monacolin K can lower LDL cholesterol, offering a potential alternative for managing high cholesterol.

## Contribution

A meta-analysis showing monacolin K's effectiveness in reducing LDL-C levels in individuals not responding to standard therapies.

## Key findings

- Monacolin K supplements significantly lower LDL cholesterol levels.
- The effect is consistent across different doses and durations of supplementation.
- Monacolin K may serve as an alternative for those intolerant to statins.

## Abstract

Natural products have gained attention as alternative strategies for managing dyslipidemia, particularly in individuals who are resistant or unwilling to use conventional pharmacotherapies. Monacolin K, a compound derived from natural sources, has demonstrated potential benefits in improving lipid profile indices across various doses and supplementation durations. This study aimed to quantitatively evaluate the effects of monacolin K‐containing products on plasma lipid levels through a meta‐analysis of clinical trials.

Data were extracted from studies that included placebo or inactive control groups, and the analysis was conducted using Comprehensive Meta‐Analysis (CMA) V4 software.

Our findings indicate that monacolin K‐containing supplements are effective in lowering lipid levels, particularly low‐density lipoprotein cholesterol (LDL‐C).

These results highlight the potential of monacolin K as a promising adjunct therapy for hypercholesterolemia management, especially for patients who have not achieved LDL‐C targets with standard care or are intolerant to or unwilling to use statin therapy.